Company intelligence / Profile preview
Phenomic AI
Toronto, Ontario, Canadaphenomic.ai ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Phenomic AI has validated two cancer drug targets discovered with their platform and is advancing them into preclinical studies[5][6].
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- Antibodies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Boehringer Ingelheim ($509M collaboration)[4]Astellas Pharma (Strategic research collaboration for solid tumor cell therapies)[8]
Beyond the preview
Go deeper on Phenomic AI.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phenomic AI.